Using lasers, engineers have developed a new ceramic welding technology that works in ambient conditions, making it more practical than traditional methods that require melting the parts in a furnace at extremely high temperatures. This could make it possible to build ceramic-encased electronics.
In a survey, UC San Diego researchers report most patients are willing to share medical records for research purposes, with a few caveats.
Researchers have discovered the root cause of why lithium metal batteries fail, challenging a long-held belief in the field. The study presents new ways to boost battery performance and brings research a step closer to incorporating lithium anodes into rechargeable batteries.
University of California San Diego School of Medicine researchers identified a new therapeutic approach in mouse models that halts drug resistance and cancer progression by using an antibody that induces the immune system via macrophages to seek and kill cancer cells.
UC San Diego School of Medicine has been awarded $9 million to fund research projects using human pluripotent stem cells, CRISPR and human organoids to dissect beta cell defects and create a human cell model of type 1 diabetes aimed at identifying the cellular actions leading to disease onset.
UC San Diego researchers discovered that removing a single enzyme in mice dramatically boosts survival from sepsis, an often fatal over-reaction of the immune system to infection. The finding provides a new and unexpected therapeutic target for new drug development.
UC San Diego engineers have developed the thinnest optical device in the world: a waveguide that is three layers of atoms thin. The work is a proof of concept for scaling down optical devices to sizes that are orders of magnitude smaller than today’s devices.
The multiple sclerosis drug teriflunomide, paired with targeted cancer therapy, markedly shrinks patient-derived glioblastomas grown in mice by reaching stem cells at the tumor’s root, according to a new UC San Diego School of Medicine study published in Science Translational Medicine.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.